December 22, 2021 | Health Care | Europe | Ended
On 14-Dec-21, following nearly two weeks of takeover speculation, Australian biopharma giant CSL entered into a definitive agreement to acquire Swiss speciality pharma company, Vifor Pharma, for USD 11.7bn, or USD 179.25 per share. The deal is structured as an all-cash tender offer and is at a 61% premium to Vifor’s undisturbed price on 1-Dec-21, before the market speculated on a possible bid. Vifor’s board unanimously recommends the offer, which is subject to regulatory approvals and an 80% minimum acceptance threshold. Patinex (private), Vifor’s largest shareholder ...
Please contact us to request access to this report.